The approval of non-immunosuppressive and immunosuppressive novel therapies is revolutionizing the IgAN treatment landscape, which is rapidly evolving beyond traditional standard of care therapies like RAASi. Additionally, recent clinical evidence demonstrated the potential of combined therapies to maximize proteinuria reduction in alignment with evolving clinical practice guideline recommendations. This symposium delves into the latest advances in IgAN care, and case-based insights and practical strategies will be provided to highlight the critical need to achieve the lowest possible proteinuria levels in patients with IgAN and to optimize individualized patient care.
Click here to register for the ERA Congress.
The ERA assumes no responsibility for the information published on this website.
Revolutionizing IgAN Care in the Era of Precision Medicine: Diagnostic Approaches, Evolving Guidelines, and Novel Therapies
Transcript
Revolutionizing IgAN Care in the Era of Precision Medicine: Diagnostic Approaches, Evolving Guidelines, and Novel Therapies
closeReady to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
Overview
The approval of non-immunosuppressive and immunosuppressive novel therapies is revolutionizing the IgAN treatment landscape, which is rapidly evolving beyond traditional standard of care therapies like RAASi. Additionally, recent clinical evidence demonstrated the potential of combined therapies to maximize proteinuria reduction in alignment with evolving clinical practice guideline recommendations. This symposium delves into the latest advances in IgAN care, and case-based insights and practical strategies will be provided to highlight the critical need to achieve the lowest possible proteinuria levels in patients with IgAN and to optimize individualized patient care.
Click here to register for the ERA Congress.
The ERA assumes no responsibility for the information published on this website.Provider(s)/Educational Partner(s)
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?